Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Cellular and Immunological Approaches to Prevent Relapse: Pediatric Blood and Marrow Transplant Consortium (PBMTC). For a description of this project, see the consortium grant made to the lead institution: National Marrow Donor Program, Minneapolis, MN.

Through this partnership with The Kids' Cancer Project, proceeds from St. Baldrick's events in Australia fund life-saving research in Australia.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pediatric Blood & Marrow Transplant Consortium. For a description of this project, see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: the Pediatric Blood & Marrow Transplant Consortium. For a description of this project, "Innovative Pilot Trials in Pediatric HSCT for Malignancies-PBMTC Core Grant," see the consortium grant made to the lead institution: the National Marrow Donor Program, Minneapolis, MN.

Through this partnership with The Children's Hospital at Westmead, proceeds from St. Baldrick's events in Australia fund life-saving research in Australia.

This institution is a member of the Children’s Oncology Group (COG).  From the first event in 2000 through 2004, St. Baldrick’s funds benefitted the COG.  Since the St. Baldrick’s Foundation began making grants in 2005, each of the 200 member institutions of the COG has received a portion of a multi-million dollar St. Baldrick’s grant every year.  These funds have been distributed based on the number of patients at each institution who are treated on COG clinical trials, their best hope for a cure.

This institution is a member of the Children's Oncology Group (COG). From the first event in 2000 until 2004, St. Baldrick's funds benefited the COG. Since the St. Baldrick's Foundation began making grants in 2005, each of the 200 member institutions of the COG has received a portion of a multi-million dollar St. Baldrick's grant every year. These funds have been distributed based on the number of patients at each institution who are treated on COG clinical trials, their best hope for a cure.